Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
GlobalData on MSN15d
FDA approves Zydus’ Phase IIb trial of Usnoflast for ALS treatmentThe US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...
Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS ...
Study finding Xenon gas could protect against Alzheimer’s disease leads to start of clinical trial
New research from Mass General Brigham and Washington University School of Medicine in St. Louis found Xenon gas inhalation reduced neurodegeneration and boosted protection in preclinical models o ...
Fast forward to 2025: xenon, an odourless noble gas in Group 18 of the periodic table, is now offering hope for Alzheimer’s ...
Microglia, the brain's primary and most prominent immune ... for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of ...
Microglia, the brain's primary and most prominent immune ... for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of ...
Microglia, the brain's primary and most prominent immune ... for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of ...
a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS). Under the leadership of Principal Investigator Prof Merit Cudkowicz, MD, Director of the Sean M. Healey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback